Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer.
10.3346/jkms.2008.23.4.598
- Author:
Jae Young JOUNG
1
;
Kyung Seok HAN
;
Taek Sang KIM
;
Ho Kyung SEO
;
Jinsoo CHUNG
;
Kang Hyun LEE
Author Information
1. Urologic Oncology Clinic, Institute and Hospital, National Cancer Center, Goyang, Korea. uroonco@ncc.re.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Urinary Bladder Neoplasms;
Cisplatin;
Combined Modality Treatment
- MeSH:
Cisplatin/therapeutic use;
Combined Modality Therapy;
Female;
Humans;
Male;
Muscle Neoplasms/pathology;
Neoplasm Invasiveness;
Salvage Therapy;
Urinary Bladder Neoplasms/mortality/pathology/*therapy
- From:Journal of Korean Medical Science
2008;23(4):598-603
- CountryRepublic of Korea
- Language:English
-
Abstract:
The authors designed this study to determine the clinical effectiveness of trimodality treatment, i.e., transurethral resection of a bladder tumor (TURBT) and concurrent chemoradiotherapy (CRT). Twenty patients with a muscle-invasive bladder cancer were treated by TURBT followed by concurrent cisplatin (75 mg/m(2) day), administered on weeks 1 and 4 of radiotherapy. According to residual tumor status after TURBT, patients were classified into patients with a complete TURBT group and incomplete TURBT group. Response to treatment was evaluated by restaging TURBT at 4 weeks after completing CRT (post-CRT). Fifteen patients (75%) achieved complete remission (CR) at restaging; 10 patients (50%) remained continuously free of tumor recurrence. Disease-specific and overall survivals were 51.1% and 38.6% at 5 yr post-CRT, respectively. Of 16 patients in the complete TURBT group, 14 patients (87.5%) achieved CR, which was significantly different from that observed in the incomplete TURBT group, in which only 1 (25%) of 4 patients achieved CR (p=0.032). Five- year disease-specific and overall survivals were 71.6% and 53.5%, respectively. Ten patients (90.9%) maintained their own bladder among the 11 surviving patients. Trimodality treatment was found to be an effective treatment in patients who underwent complete TURBT for a muscle-invasive bladder cancer.
